A novel antithrombotic effect of sulforaphane via activation of platelet adenylate cyclase: Ex vivo and in vivo studies

Medicine & Life Sciences

• sulforafan 87%
• Platelet Activation 66%
• Adenylyl Cyclases 61%
• Protein Kinase C 23%
• p38 Mitogen-Activated Protein Kinases 20%
• Phosphorylation 17%
• vasodilator-stimulated phosphoprotein 15%
• Brassica 13%
• Protein Kinase Inhibitors 10%
• Platelet Aggregation 10%
• Phosphatidylinositol 3-Kinases 10%
• 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one 7%
• Collagen 7%
• Adenylyl Cyclase Inhibitors 7%
• Cardiovascular Diseases 7%
• isothiocyanic acid 6%
• Guanylate Cyclase 6%
• SB 203580 6%
• 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 6%
• Protein C Inhibitor 6%
• Cyclic GMP 5%
• Type C Phospholipases 5%
• Hydroxyl Radical 5%
• Growth 5%
• Adenosine Diphosphate 5%
• Mitogen-Activated Protein Kinases 5%
• Pulmonary Embolism 5%
• Vegetables 5%
• Cyclic AMP 4%
• Blood Platelets 3%
• Thrombosis 3%
• Neoplasms 3%
• Mortality 2%
• Therapeutics 1%

Chemical Compounds

• Sulforaphane 100%
• Protein 15%
• Collagen 10%
• LY294002 10%
• Phosphatidylinositol 3 Kinase Inhibitor 9%
• EC 2.7.12.2 (Mitogen-Activated Protein Kinase Kinase) Inhibitor 8%
• Protein Kinase C Inhibitor 8%
• Anticoagulant Agent 7%
• Isothiocyanate 6%